KMT2A rearranged AML is associated with a poor prognosis, with a notable exception of t(9;11)(p21;q23)/KMT2A::MLLT3, which confers an intermediate prognosis [2]. This evidence concerns the gene MLLT3 and acute myeloid leukemia.